SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study

Inclusion Criteria: 1. Adult, \>18 years old 2. Angiographically-confirmed significant femoro-popliteal (FP) stenosis or occlusion by atherosclerosis 3. Successful FP intervention; residual stenosis \<30% 4. Without significant residual inflow disease; Intact iliac artery inflow (with or without intervention of iliac or below knee arteries) 5. patent outflow status; at least 1 arterial runoff in below knee arteries 6. All kind of fem-pop intervention including POBA, stent, DCB, DES for TASC A\~ D Exclusion Criteria: 1. At risk of hemorrhage, bleeding tendency or thrombophilia 2. Acute limb ischemia / inflammatory arterial disease 3. Contraindication or allergic to ASA, clopidogrel, Anplone 4. Medication of warfarin 5. Pregnancy, hepatic dysfunction, thrombocytopenia 6. Previous FP bypass or intervention 7. Impossible to stop clopidogrel before EVT